

PIPELINE OF INVESTIGATIONAL THERAPIES#:

PROGRAM (TARGET)	THERAPEUTIC AREA	INDICATION	PHASE 1	PHASE 2	PHASE 3
valbenazine* (VMAT2 Inhibitor)	Neuropsychiatry	Adjunctive Treatment of Schizophrenia			
valbenazine* (VMAT2 Inhibitor)	Neurology	Dyskinetic Cerebral Palsy			
osavampator/NBI-'845‡ (AMPA)	Neuropsychiatry	Inadequate Response to Treatment in Major Depressive Disorder			
NBI-'568 <sup>  </sup> (M4 Agonist)	Neuropsychiatry	Schizophrenia			
NBI-'770 <sup>§</sup> (NMDA NR2B NAM)	Neuropsychiatry	Major Depressive Disorder			
NBI-'570 <sup>  </sup> (M1/M4 Agonist)	Neuropsychiatry	Schizophrenia-CNS Indications			
NBI-'567 <sup>  , ¶</sup> (M1 Agonist)	Neuropsychiatry	CNS Indications			
NBI-'569 <sup>  </sup> (M4 Agonist)	Neuropsychiatry	CNS Indications			
NBI-'986 (M4 Antagonist)	Neurology	Movement Disorders			
NBI-'890 (VMAT2 Inhibitor)	Neuropsychiatry	CNS Indications			
NBI-'355 (Na <sub>v</sub> 1.2/1.6)	Neurology	Epilepsy			
NBI-'675 <sup>**</sup> (VMAT2 Inhibitor)	Neuropsychiatry	CNS Indications			

Neurocrine Biosciences has global rights, unless otherwise noted.

\*Mitsubishi Tanabe Pharma Corporation has commercialization rights in Japan and other select Asian markets.

‡Takeda Pharmaceutical Company Limited has retained rights in Japan.

§Licensed from Takeda Pharmaceutical Company Limited.

<sup>||</sup> Licensed from Nxera Pharma (formerly Sosei Heptares).

<sup>¶</sup>Nxera Pharma (formerly Sosei Heptares) has retained rights in Japan; Neurocrine Biosciences may opt-in to a 50:50 cost and revenue share upon certain development events.

<sup>\*\*</sup>Phase I Initiating in Q1.

# Investigational therapies are not approved for use in any country

